Clay B. Siegall, Ph.D., began his academic career in Zoology at the University of Maryland. He then earned his Ph.D. in Genetics from George Washington University. From 1988 to 1991, he worked at the National Institute of Health. He then took his expertise in scientific research to Bristol-Myers Squibb Pharmaceutical Research Institute from 1991-1997 where he developed a professional foundation built on scientific innovation forged through exacting research.
With his focus on cancer therapies and a deep-seated need to help patients, it led him to the formation in 1998 of Seattle Genetics, a biotechnology company of which Dr. Clay Siegall serves as President, Chief Executive Officer and Chairman of its Board. As the driving force of this company, Dr. Siegall has moved the company forward into a variety of strategic licenses based on its ADC technology that has procured over $350 million. In 2012, Dr. Siegall was named by Ernst & Young as the Pacific Northwest Entrepreneur of the Year. He is also the author of over 70 publications and the holder of 15 patents.
In a recent interview with Inspirery, Dr. Siegall discussed his focus at Seattle Genetics as the development of antibody-based therapies. HE said that in the last five years, his team at Seattle Genetics was able to develop antibody-drug conjugates, (ADCs), and acquired an FDA approval of the company’s first ADC product, ADCETRIS, in 2011, which is now used and endorsed in over 65 countries. Additionally, he foresees that Seattle Genetics is moving forward with development on a distinct and varied portfolio of proprietary ADCs for patients in treating cancer.
Dr. Siegall also discussed how long it took Seattle Genetics to become profitable and he said that the company really came into its own when they partnered with Bayer in 2009 for the submission of a fact-finding new drug application with the FDA. Shortly after, they began clinical trials of their flagship pharmaceutical, ADCETRIS.
In the last few months his biggest decision, in terms of business, had to do with expansion and foreshadowing the bigger picture for a company is always the toughest decision. Just as some companies have had to face downsizing, expansion can leave people in any company where they do not want to be, or even without a job. But, he has committed himself to doing what he feels is the most important research in his field, and to try to develop, at Seattle Genetics, the most innovative research that he can.